AIDS vaccines: concepts and first trials.

Area of Science:

• Immunology
• Virology
• Vaccinology

Background:

• Human Immunodeficiency Virus (HIV) and Simian Immunodeficiency Virus (SIV) are lentiviruses that establish persistent infections.
• These viruses employ sophisticated mechanisms like latency and variability to evade host immune responses.
• Significant challenges exist in understanding whether the immune response to HIV is ultimately beneficial or detrimental to the host.

Purpose of the Study:

• To review the virological and immunological obstacles hindering the development of an effective AIDS vaccine.
• To discuss current vaccine strategies being tested and their potential based on animal models.

Main Methods:

• Review of scientific literature on HIV/SIV virology and immunology.
• Analysis of ongoing empirical trials for various vaccine types (live attenuated, recombinant, inactivated, subunit, anti-idiotypes, synthetic, chimeric).
• Evaluation of animal models, specifically macaques infected with SIV, for vaccine efficacy testing.

Main Results:

• Virological obstacles include viral latency (antigenic invisibility) and variability (antigenic shift, adaptation).
• Immunological obstacles involve the complex role of the immune response and HIV-induced immunosuppression.
• Promising results have been observed with inactivated virus vaccines in SIV-infected macaque models.

Conclusions:

• Overcoming latency and variability are key virological challenges for AIDS vaccine development.
• The net effect of the immune response against HIV remains a critical unanswered question.
• Inactivated virus vaccines, particularly in SIV-infected macaques, represent a promising avenue for future AIDS vaccine research.